3D-QSAR study of tetrahydro-3H-imidazo[4,5-c]pyridine derivatives as VEGFR-2 kinase inhibitors using various charge schemes

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Archives of pharmacal research

• Publication date

  2015-01-13

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s12272-015-0554-2PMID 25874606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Docking-based 3D-QSAR study of pyridyl aminothiazole derivatives as checkpoint kinase 1 inhibitors

  2014cited by this paper
• Nanobiomaterials for pharmaceutical and medical applications

  2014cited by this paper
• In silico study on indole derivatives as anti HIV-1 agents: a combined docking, molecular dynamics and 3D-QSAR study

  2013cited by this paper
• Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.

  2012cited by this paper
• Various atomic charge calculation schemes of CoMFA on HIF‐1 inhibitors of moracin analogs

  2012cited by this paper
• Large variation in electrostatic contours upon addition of steric parameters and the effect of charge calculation schemes in CoMFA on mutagenicity of MX analogues

  2012cited by this paper
• Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

  2009cited by this paper
• VEGF receptor signalling ? in control of vascular function

  2006cited by this paper
• Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.

  2005cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

  2004cited by this paper
• Angiogenesis in health and disease

  2003cited by this paper
• Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

  2003cited by this paper
• Tyrosine kinases as targets in cancer therapy – successes and failures

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.

  2002cited by this paper
• Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation

  2002cited by this paper
• FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.

  2001cited by this paper
• Angiogenesis: a therapeutic target in arthritis.

  2001cited by this paper
• Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method

  2000cited by this paper
• The role of VEGF and thrombospondins in skin angiogenesis.

  2000cited by this paper
• VEGF receptor signaling in tumor angiogenesis.

  2000cited by this paper
• The protein tyrosine kinase family of the human genome

  2000cited by this paper
• MMFF VI. MMFF94s option for energy minimization studies

  1999cited by this paper
• Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

  1999cited by this paper
• Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

  1994cited by this paper
• Affective disorders and endocrine disease. New insights from psychosomatic studies.

  1994cited by this paper
• Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

  1994cited by this paper
• Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

  1991cited by this paper
• Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies

  1988cited by this paper
• Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

  1988cited by this paper
• The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses

  1984cited by this paper
• ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES

  1980cited by this paper
• A new model for calculating atomic charges in molecules

  1978cited by this paper
• Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors

  1972cited by this paper
• Sur les rôles respectifs des électrons σ et π dans les propriétés des dérivés halogénés des molécules conjuguées. Application à l'étude de l'uracile et du fluorouracile

  1967cited by this paper
• 812. A simple MO–LCAO method for the calculation of charge distributions in saturated organic molecules

  1958cited by this paper

• Current Computational Approaches for the Discovery of Novel Anticancer Agents Targeting VEGFR and SIRT Signaling Pathways.

  2026cites this paper
• Discovery of pyridine- sulfonamide hybrids as a new scaffold for the development of potential VEGFR-2 inhibitors and apoptosis inducers.

  2021cites this paper
• 3D-QSAR, docking, molecular dynamics simulation and free energy calculation studies of some pyrimidine derivatives as novel JAK3 inhibitors

  2017cites this paper
• Design of Novel Chemotherapeutic Agents Targeting Checkpoint Kinase 1 Using 3D-QSAR Modeling and Molecular Docking Methods.

  2016cites this paper
• Determination of structural requirements of Mer kinase inhibitors and binding interaction analysis using in silico approaches

  2016cites this paper
• The FHIT gene product: tumor suppressor and genome “caretaker”

  2014cites this paper